title: A Reactive (1)O2 - Responsive Combined Treatment System of Photodynamic and Chemotherapy for Cancer.
abstract: The development of reactive oxygen species (ROS)-responsive drug delivery and drug release has gradually attracted much attention in recent years as a promising therapeutic strategy. Singlet oxygen ((1)O2) as the major ROS species is widely used in photodynamic therapy (PDT) of cancer. In the present study, we introduce a combined treatment using ROS-sensitive thioketal (TK) linkage as a linker between upconversion nanoparticles (UNs)-based PDT and doxorubicin (DOX)-based chemotherapy. UNs can not only play a role in PDT, but can also be used as a nanocarrier for drug delivery of DOX. Moreover, the products of (1)O2 during PDT are able to cleave TK linker inducing the release of DOX which can further achieve the goal of chemotherapy. By using this (1)O2-responsive nanocarrier delivery system, DOX can easily reach the tumor site and be accumulated in the nuclei to effectively kill the cancer cells, and therefore decreasing the side effects of chemotherapy on the body. Thus, PDT also has the function of controlling drug release in this combination treatment strategy. Compared with monotherapy, the combination of PDT with chemotherapy also possesses excellent drug loading capability and anticancer efficiency.
authors.affiliation: Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.|University of Chinese Academy of Sciences, Beijing 100049, China.
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Wang
authors.affiliation: Life Sciences Department, Heze University, Heze 274015, China.
authors.forename: Guoqing
authors.initials: G
authors.lastname: Meng
authors.affiliation: Shandong Provincial Key Laboratory of Microbial Engineering, Qilu University of Technology, Jinan 250100, China.
authors.forename: Song
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Shandong Provincial Key Laboratory of Microbial Engineering, Qilu University of Technology, Jinan 250100, China.
authors.forename: Xinli
authors.initials: X
authors.lastname: Liu
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D065546:Drug Liberation; D006801:Humans; D008546:Melanoma, Experimental / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D053758:Nanoparticles / Q000648:ultrastructure; D010316:Particle Size; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000494:pharmacology / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000737:chemistry; D017382:Reactive Oxygen Species / Q000378:metabolism*; D026082:Singlet Oxygen / Q000378:metabolism; D012996:Solutions; D055672:Static Electricity
chemical_list: D017319:Photosensitizing Agents; D017382:Reactive Oxygen Species; D012996:Solutions; D026082:Singlet Oxygen; D011092:Polyethylene Glycols; D004317:Doxorubicin